Announcements Trials

Browse Landscape

Phase

Status

Terminated 2 Unknown 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 28 Breast Diseases 3 Advanced Breast Cancer 2 Vitamin D Deficiency 1 Triple Negative Breast Neoplasms 1 Recurrence 1 Obesity 1 Nutrition Disorders 1 Neoplasms 1 Neoplasm Metastasis 1 Inflammatory Breast Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma 1 Camurati-Engelmann Syndrome 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Carcinoma In Situ 1 Breast Cancer Organoids 1 Arthritis 1 Arthralgia 1

Interventions

Carboplatin 15 camrelizumab 11 Capecitabine 11 130-nm albumin-bound paclitaxel 10 pembrolizumab 8 eribulin 8 Paclitaxel 8 Cyclophosphamide 8 Epirubicin 7 Gemcitabine 6 Cisplatin 6 tislelizumab 5 apatinib 5 atezolizumab 4 anlotinib 4 Taxes 4 Nivolumab 4 Docetaxel 4 Bevacizumab 4 toripalimab 3 Vinorelbine 3 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3 Doxorubicin 3 Albumin-Bound Paclitaxel 3 talazoparib 2 spartalizumab 2 olaparib 2 fluzoparib 2 famitinib 2 Zoledronic Acid 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Triple Negative Breast Neoplasms × Anastrozole × Clear all

NCT02089854 2016-12-02

AETNBC

Peking Union Medical College Hospital

Phase 4 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡